325 related articles for article (PubMed ID: 26014955)
1. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955
[TBL] [Abstract][Full Text] [Related]
2. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.
Hendrickx S; Boulet G; Mondelaers A; Dujardin JC; Rijal S; Lachaud L; Cos P; Delputte P; Maes L
Parasitol Res; 2014 May; 113(5):1875-81. PubMed ID: 24615359
[TBL] [Abstract][Full Text] [Related]
3. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
Hendrickx S; Beyers J; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2016 Jul; 71(7):1914-21. PubMed ID: 27084919
[TBL] [Abstract][Full Text] [Related]
4. Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
Hendrickx S; Inocêncio da Luz RA; Bhandari V; Kuypers K; Shaw CD; Lonchamp J; Salotra P; Carter K; Sundar S; Rijal S; Dujardin JC; Cos P; Maes L
PLoS Negl Trop Dis; 2012; 6(5):e1664. PubMed ID: 22666513
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.
Hendrickx S; Bulté D; Van den Kerkhof M; Cos P; Delputte P; Maes L; Caljon G
Int J Parasitol Drugs Drug Resist; 2019 Apr; 9():1-7. PubMed ID: 30562667
[TBL] [Abstract][Full Text] [Related]
7. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
8. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
9. Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.
Mondelaers A; Sanchez-Cañete MP; Hendrickx S; Eberhardt E; Garcia-Hernandez R; Lachaud L; Cotton J; Sanders M; Cuypers B; Imamura H; Dujardin JC; Delputte P; Cos P; Caljon G; Gamarro F; Castanys S; Maes L
PLoS One; 2016; 11(4):e0154101. PubMed ID: 27123924
[TBL] [Abstract][Full Text] [Related]
10. Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.
Rastrojo A; García-Hernández R; Vargas P; Camacho E; Corvo L; Imamura H; Dujardin JC; Castanys S; Aguado B; Gamarro F; Requena JM
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):246-264. PubMed ID: 29689531
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.
Verma A; Bhandari V; Deep DK; Sundar S; Dujardin JC; Singh R; Salotra P
Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):370-377. PubMed ID: 29035735
[TBL] [Abstract][Full Text] [Related]
12. Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum.
Hendrickx S; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
Parasitol Res; 2015 Jul; 114(7):2561-5. PubMed ID: 25877390
[TBL] [Abstract][Full Text] [Related]
13. Genomic and Metabolomic Polymorphism among Experimentally Selected Paromomycin-Resistant Leishmania donovani Strains.
Shaw CD; Imamura H; Downing T; Blackburn G; Westrop GD; Cotton JA; Berriman M; Sanders M; Rijal S; Coombs GH; Dujardin JC; Carter KC
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658971
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
Hendrickx S; Van Bockstal L; Bulté D; Mondelaers A; Aslan H; Rivas L; Maes L; Caljon G
Parasit Vectors; 2020 Feb; 13(1):96. PubMed ID: 32087758
[TBL] [Abstract][Full Text] [Related]
15. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
[TBL] [Abstract][Full Text] [Related]
16. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
Sane SA; Shakya N; Gupta S
Exp Parasitol; 2011 Feb; 127(2):376-81. PubMed ID: 20846525
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
20. Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.
Hendrickx S; Leemans A; Mondelaers A; Rijal S; Khanal B; Dujardin JC; Delputte P; Cos P; Maes L
PLoS One; 2015; 10(10):e0140139. PubMed ID: 26469696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
